Guidelines and accompanying risk charts concerning cardiovascular risk management (CVRM) are regularly revised worldwide.
INTRODUCTION
In primary preventive cardiovascular disease (CVD) care, risk classification -based on a patient's absolute risk of developing CVD as calculated by combining several risk factors -is widely used. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Increasing knowledge about the underlying assumptions and calculations of these risk classification systems, and about the effects of interventions, leads to regular revisions of guidelines. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Like in many other countries, the first Dutch guidelines on the prevention of CVD introduced by the Dutch College of General Practitioners, had a 'single risk factor approach', i.e. they looked at either blood pressure, or cholesterol levels, or at diabetes as a risk factor, but the risk factors were not combined into an integrated approach of risk management. [15] [16] [17] In 2006, the first comprehensive guideline on cardiovascular risk management (CVRM) was introduced. 18 Five risk factors for CVD, i.e. age, sex, smoking status, systolic blood pressure (SBP) and total cholesterol/high-density-lipoprotein cholesterol (TC/HDL) ratio, were integrated into one risk chart depicting absolute cardiovascular risk. This risk chart was based on the SCORE risk function, as described in the European guideline developed by the Third Joint Task Force 2003. 19 A patient's 10-year risk of cardiovascular mortality was calculated, and the need for preventive medication was assessed accordingly, using a 10%, 10-year risk on cardiovascular mortality as threshold for entering the high-risk category. The latest European guideline on CVD prevention was published in 2012, presenting a risk chart for high CVD risk countries and low CVD risk countries. 8 In the Netherlands, a new guideline on CVRM was launched in 2012 as well, presenting a risk chart based on the European risk chart for low CVD risk countries. 20 This new guideline included some differences regarding the calculation of CVD risk; differences that are also seen in recent updates of other CVD prevention guidelines. 1, 2, 7, 8, 11, 12 The first difference is that the age range now is set at 40 -70 years instead of 40 -65 years; second, cardiovascular risk assessment is now based on both cardiovascular mortality and morbidity; third, a 20% 10 -year risk of cardiovascular mortality and morbidity was now chosen as the threshold for entering the high-risk category; and finally, the additional risks by diabetes mellitus and rheumatoid arthritis were quantified into the risk chart. At first glance, this 2012 guideline identifies more patients requiring preventive medication than the 2006 guideline. However, due to other differences between the two versions (especially the weight of additional risk-increasing factors) the exact implications of the 2012 revision on an individual level are not known.
Although the CVRM guidelines in other countries are also regularly revised and most of them present risk charts, 1, 2, 5-10 to our knowledge the effects of a change of guidelines at the population level have not yet been examined. Therefore, we used data from 19 general practices in the western part of the Netherlands to assess whether patients using preventive cardiovascular medication would shift in risk category according to the most recent revision of the Dutch CVRM guideline, and whether these patients would shift in drug recommendation.
METHODS

Study population
A cross-sectional study was performed with data from the Registration Network of General Practices associated with Leiden University (RNUH -LEO); this is a longitudinal database of electronic medical records (EMRs) of all patients (approximately 30 000) enlisted with 19 regular general practitioners (GPs) (located in four healthcare centres) in the western part of the Netherlands.
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Medical records of patients aged 40 -65 years who were using antihypertensive treatment (anatomical therapeutic chemical codes C02*, C03*, C07*, C08*, C09*) and/ or lipid-lowering drugs (C10*) during the whole year 2011 were selected. 22 All medical records of patients with previous atherothrombotic CVD (international classification of primary care (ICPC) codes K75, K76*, K89, K90*, K91, K92*, K99*) and not using platelet aggregation inhibitors excluding heparin (anatomical therapeutic chemical code B01AC), providing an undisputed indication for medication, were excluded. 23 Medical records of patients with diabetes mellitus (T90*) or rheumatoid arthritis (L88*) were also excluded, as inclusion of medical records of these patients would lead to an overestimation of reclassifications because only the 2012 guideline takes these two diseases into account as quantifiable risk-increasing factors. With these criteria, 2075 medical records of patients were selected.
Classification in risk charts
Based on data in the medical records, we calculated the patient's 10-year cardiovascular risk before start of treatment according to the 2006 and 2012 risk charts respectively, using age, sex, smoking status, pre-treatment SBP and pre-treatment TC/HDL ratio, and assessed the risk category and drug recommendation for each patient according to both guidelines. Pre-treatment values were selected closest to the date the medication was started, up to one year before the start of medication. The same was done for smoking status, except that when the patient was registered as a non-smoker or a former smoker longer than one year ago, we considered the patient a current non-smoker. 
Statistical analysis
Patients' shifts in the risk category and drug recommendation were described using frequency tables. Using an independent t -test, mean cardiovascular risk was compared between the group shifting in risk category and the non-shifting group, as well as for the group shifting in drug recommendation versus the group not shifting in drug recommendation. The odds ratios of risk factors for shift in risk category or drug recommendation were calculated with logistic regression analysis to explore further the differences between these groups. We rounded to whole patient numbers in all our analyses. 
Missing patient data
Sensitivity analysis
Shifts in risk category as described above were compared with the original dataset and with a set with imputed data without range restrictions. All analyses were performed with the IBM SPSS version 20.
RESULTS
Patient characteristics
Mean age of the patients was 55.4 years (SD 3.9), 50.2% were men (range: 49.2 -51.2), 16% were smokers (range: 15 -18%), mean SBP was 153 mmHg (SD 16.7), and the mean TC/HDL ratio was 5.0 (SD 1.0). Due to the different values of SBP and TC/HDL ratio in the imputed datasets, the number of patients fulfilling guideline criteria differed per dataset. On average 827 (range: 792 -841) out of 2075 patients did not fit the guideline, leading to an eligible study population of on average 1248 patients (range: 1234 -1283).
Shifts in risk category and drug recommendation
The percentage of patients remaining in the same risk category was 80% [(999/1248) * 100]. Furthermore, 726 patients (58.2% of all patients) had a low risk according to the 2012 guideline despite being treated with preventive medication (Table 2) . Table 2) . Table 3 shows the differences between the group shifting in drug recommendation and the group not shifting in drug recommendation. Differences were found for age, SBP and TC/HDL ratio: i.e. the higher the age, SBP or the TC/HDL ratio, the greater the probability that a patient would shift in drug recommendation. Moreover, being male also increased the probability of shifting in drug recommendation. 
Predictors of shift in drug recommendation
Sensitivity analysis
When we imputed data without range restrictions, there was no difference in the percentage of shifts in risk category compared to the shifts in risk category mentioned above (data not shown). The same results emerged from the complete case analysis (n = 236).
DISCUSSION
Main findings
In our primary care cohort, revision of the guideline on cardiovascular risk management led to a shift in risk category in one in five patients (20%) and to a concomitant shift in drug recommendation in 12% of the patients. In addition, the finding that about 60% of the patients use preventive medication whilst having a low risk suggests considerable overtreatment of low-risk patients.
Strengths and limitations
Data for the present study were based on patients' EMRs because, in the Netherlands, CVRM is predominantly primary care based, and all Dutch citizens are enlisted with a general practice. This ensures that our cohort is a representative sample from the general population that is eligible for primary preventive cardiovascular care. Sampling from a large cohort of patients strengthens the external validity of our results. Moreover, over 96% of the problems registered in the EMRs of the healthcare centres of RNUH -LEO are coded with an ICPC code (which is higher than in the average Dutch general practices), ensuring a reliable selection of our study participants. 25 We imputed 48.1 -50.2% of the SBP, TC/HDL ratio and smoking status-values in the dataset to be able to calculate 10-year cardiovascular risk. This may be a true reflection of the incompleteness of relevant data before deciding on the prescription of preventive medication, but can also be due to the incomplete registration of data in the EMRs. However, the imputed dataset showed the same percentage of shifts in the risk category as the complete case analysis.
Comparison with existing literature
In an earlier study, we found that 61.4% of the patients had a predicted low cardiovascular 10-year risk according to the 2006 Dutch CVRM guideline before start of medication, compared with 70.6% (based on the 2006 version) in the present study. 26 Besides this confirmation in a new patient population, the present study reports on the implications of a guideline revision at a population level with regard to shifts in risk categories and drug recommendations. Scheltens et al., compared the Framingham risk score with the SCORE risk function with regard to the number of patients assigned to treatment; a difference with our study is that we examined an actually revised guideline, making the present study less hypothetical. 27 Another additional aspect of this study is that we report the determinants of the patients who shifted in drug recommendation, which can be helpful in daily practice.
In this study, we observed that about 60% of the patients use preventive medication whilst having a low risk. This can be explained by former guidelines (before the guideline on integrated CVRM was issued) recommending preventive medication based on a single risk factor ('hypertension' or 'hypercholesterolemia', etc.) without taking other risk factors (e.g. age, sex and smoking status) into account and not integrating the risk. It is likely that also a considerable number of low-risk patients in other European countries are unnecessarily treated as well. For example in Germany, as in the Netherlands, the concept of starting treatment based on the total burden of risk was adopted only recently, 9, 17 although the European guideline adopted this idea much earlier.
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Implications for research and practice GPs should be aware that a revised guideline in the area of primary prevention of CVD could have consequences for their patients: it is advisable to re-evaluate drug recommendations in patients assessed according to the former guideline and not yet using preventive treatment. Then again, a large proportion of patients seem to use medication without a clear indication, irrespective of the version of the guideline used. It remains unclear how to proceed when a revised guideline has a higher threshold for starting preventive medication, resulting in situations where patients may well be advised to stop taking preventive medication they have been using, sometimes for years on a row. Obviously, it is important to establish whether withdrawal of medication in patients with low risk is safe in the long run, and whether this is efficacious and cost effective.
CONCLUSION
Revision of a guideline in the area of primary prevention of CVD may have a considerable impact on patient care since it may lead to shifts in risk categories and, accordingly, to shifts in drug recommendation. Professional medical organizations in countries with guidelines for primary preventive CVD care, especially when using risk charts, should be aware of these consequences and develop protocols for healthcare professionals on how to cope with these reclassifications.
KEY MESSAGE
-Revising the Dutch guideline on cardiovascular risk management implied a shift in drug recommendation in 12% of the patients.
-GPs should be aware of the possible consequences of guideline revisions for patients.
-Professional medical organizations should develop policies on how to cope with these consequences. 
